NeoGenomics Launches PanTracer LBx to Expand Access to Comprehensive Genomic Profiling via Liquid Biopsy (businesswire.com)

• Launch of PanTracer LBx liquid biopsy test for comprehensive genomic profiling.
• Analyzes ctDNA for mutations, fusions, and genomic alterations.
• Expands access to precision medicine for patients ineligible for tissue biopsy.

"NeoGenomics announced the launch of PanTracer LBx, a liquid biopsy test for comprehensive genomic profiling. The test uses circulating tumor DNA to detect mutations and fusions, aiming to expand access for patients unable to undergo tissue biopsy."